{"id":"amg-719","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Hematologic toxicity"}]},"_chembl":{"chemblId":"CHEMBL5872933","moleculeType":null,"molecularWeight":"498.61"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a CD3 × FLT3 bispecific T-cell engager, AMG 719 bridges cytotoxic T lymphocytes to FLT3-expressing leukemic cells, promoting T-cell activation and tumor cell lysis. This approach leverages the patient's own immune system to target AML cells that express the FLT3 receptor, which is frequently present in acute myeloid leukemia.","oneSentence":"AMG 719 is a bispecific antibody that simultaneously engages CD3 on T cells and FLT3 on acute myeloid leukemia blasts to redirect immune killing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:48.384Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), FLT3-positive"}]},"trialDetails":[{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT00038298","phase":"PHASE2","title":"A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-04","conditions":"Rheumatoid Arthritis","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AMG 719","genericName":"AMG 719","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 719 is a bispecific antibody that simultaneously engages CD3 on T cells and FLT3 on acute myeloid leukemia blasts to redirect immune killing. Used for Acute myeloid leukemia (AML), FLT3-positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}